Published

FDA set to decide on GSK's gepotidacin antibiotic in March

Summary by Pharmaphorum
The FDA starts priority review of GSK's gepotidacin, vying to become the first new-class antibiotic for uncomplicated urinary tract infections in over 20 years.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.